Results 181 to 190 of about 342,940 (312)

Anterior Knee Unloader Brace Prescription Yields Moderate Compliance Rates and Improved Clinical Function in Patients with Patellofemoral Pain

Arthroscopy, Sports Medicine, and Rehabilitation, EarlyView.
Purpose To determine clinical outcome changes and wear compliance rates associated with the use of a custom‐fit anterior knee unloader brace in a prospective cohort of patients with clinical symptoms derived from patellofemoral osteoarthritis (PFOA).
Andrew R. Phillips, Thomas Moran, Kofi K. Acheampong, Stephanie A. Boden, Erik C. Haneberg, William D. Bugbee, John P. Fulkerson, Simon Goertz, John G. Lane, Sabrina M. Strickland, Adam B. Yanke   +10 more
wiley   +1 more source

Ultrasound‐Guided Hip Pericapsular, Rectus Femoris Peritendinous, and Iliopsoas Bursa Injections Improve Extra‐articular Post‐arthroscopy Hip Pain

Arthroscopy, Sports Medicine, and Rehabilitation, EarlyView.
Purpose To determine the short‐ and medium‐term efficacy of ultrasound‐guided hip pericapsular, rectus femoris peritendinous, and iliopsoas bursa injections with anesthetic and corticosteroid to treat post‐arthroscopy hip pain, and if any operative variables correlated with response likelihood.
Meghan E. Sahr, Hanley Ong, Karthik Krishnan, Shu‐Han Wang, Danyal H. Nawabi, Theodore T. Miller   +5 more
wiley   +1 more source

Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double‐Blind, Proof‐of‐Concept Study

Arthritis &Rheumatology, EarlyView.
Objective To assess guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi‐IR). Methods Adults with active TNFi‐IR PsA (three or more tender/swollen joints) were randomized (2:1) to subcutaneous guselkumab (100 mg) +
Jose U. Scher, Iain B. McInnes, Enrique R. Soriano, Joseph F. Merola, Paul Bird, Vinod Chandran, Edaire Cheng, Elena Reynoso, Warner Chen, Maoji Li, Lianne S. Gensler, Philip J. Mease, Christopher T. Ritchlin   +12 more
wiley   +1 more source

Prolotherapy in the Treatment of Knee Osteoarthritis: How to Perform

Arthroscopy Techniques, EarlyView.
Abstract The conservative treatment of knee osteoarthritis is a challenge; since it has no cure, many patients do not want or cannot undergo surgical procedures. Among the various options, we have injectable therapies, especially the so‐called “regenerative,” such as the use of hyaluronic acid, orthobiologicals, and prolotherapy. In the latter, its use
José L. Rocha de Faria, Fabiana Alves C. Menegassi, Sandra T. N. Minamoto, Guilherme Blois V. Pereira, Fábio Henrique P. Videira, Diego G. Severgnine, Caio Gomes de Lima, José Paulo G. Aramburu Filho, Geraldo da R. Motta, João Antônio M. Guimarães, Ronaldo José Faria C. do Amaral, Bianca Gutfilen, Sergio Augusto L. de Souza, Zartur José B. Menegassi   +13 more
wiley   +1 more source

Arthroscopic Rotator Cuff Repair Using a Cable Suture‐Bridge Technique

Arthroscopy Techniques, EarlyView.
Abstract Rotator cuff tear is one of the most common diseases in sports medicine, and arthroscopic anchor suture and knotting are the main treatment. However, poor tendon‐bone healing or retear after surgery remains the main challenge in rotator cuff repair.
Jingjie Zhang, Qi Xiao, Huixiang Jiang, Huiyun Deng, Qingquan Wu, Jiapeng Zheng   +5 more
wiley   +1 more source

Step‐by‐Step Technique for Platelet‐Rich Plasma Gel Preparation and Use in Knee Osteoarthritis

Arthroscopy Techniques, EarlyView.
Abstract Knee osteoarthritis (OA) remains a leading cause of pain and disability worldwide, and current injectable options such as corticosteroids and hyaluronic acid often provide limited or short‐term benefits. Orthobiologic therapies, particularly platelet‐rich plasma (PRP), have gained attention for their regenerative and anti‐inflammatory ...
Diego Ariel de Lima, Renata Clazzer, Carlos Eduardo da Silveira Franciozi, Ávila Kelly de Medeiros Nicolau, Isadora Pereira Bandeira, Lana Lacerda de Lima, Maria Luzete Costa Cavalcante   +6 more
wiley   +1 more source

Navigating adverse immunostimulation: A practical guide for clinical researchers

British Journal of Clinical Pharmacology, EarlyView.
Problem Setting As drug development moves towards more complex products, early clinical development programmes are increasingly hampered by unwanted and/or unexpected activation of the immune system (adverse immune stimulation, AIS). Solution At the Centre for Human Drug Research, we have introduced standardized procedures to make AIS manageable, while
Juliette A. van den Noort, Anouk C. Meijs, Naomi B. Klarenbeek, Matthijs Moerland   +3 more
wiley   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Increasing the reporting of adverse drug reaction‐related hospitalizations using an ICD‐10‐based identification workflow: A multicentre study from Switzerland

British Journal of Clinical Pharmacology, EarlyView.
Background Reporting adverse drug reactions (ADRs) is essential for drug safety. In Switzerland, healthcare professionals are legally required to report serious and unlabelled ADRs, yet under‐reporting remains widespread. We tested a novel method to increase reporting of ADR‐related hospitalizations.
Georgia Anita Weber, Sophie‐Charlotte Bartel, Michael Boch, Christoph Rosen, Michael Bodmer, Balthasar Luzius Hug, Thomas Stammschulte, Patrick E. Beeler   +7 more
wiley   +1 more source

From anthelmintic to neuro‐oncology: A systematic review of mebendazole repurposing for brain tumour therapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mebendazole (MBZ), a benzimidazole anthelmintic with established clinical use, has emerged as a repurposing candidate for primary brain tumours due to its multimodal anticancer actions and central nervous system penetrance. This systematic review synthesizes preclinical and clinical evidence evaluating MBZ's efficacy, mechanisms of action ...
Ciara B. Blum, Milli McMenamin, Tessa Khoo, John M. Edwin, Prathibha Jose, Liam A. O’Callaghan   +5 more
wiley   +1 more source